Literature DB >> 19817944

Insulin therapy and type 2 diabetes: management of weight gain.

Samy I McFarlane1.   

Abstract

The potential for insulin-related weight gain in patients with type 2 diabetes presents a therapeutic dilemma and frequently leads to delays in the initiation of insulin therapy. It also poses considerable challenges when treatment is intensified. Addressing insulin-related weight gain is highly relevant to the prevention of metabolic and cardiovascular consequences in this high-risk population with type 2 diabetes. In addition to lifestyle changes (eg, diet and exercise) and available medical interventions to minimize the risk of weight gain with insulin treatment, familiarity with the weight gain patterns of different insulins may help deal with this problem. The use of basal insulin analogs may offer advantages over conventional human insulin preparations in terms of more physiologic time-action profiles, reduced risk of hypoglycemia, and reduced weight gain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19817944      PMCID: PMC8673427          DOI: 10.1111/j.1751-7176.2009.00063.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  46 in total

Review 1.  Mediators of sympathetic activation in metabolic syndrome obesity.

Authors:  Nora E Straznicky; Nina Eikelis; Elisabeth A Lambert; Murray D Esler
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

2.  Challenges to the diagnosis, evaluation, treatment, and management of clustered cardiometabolic risk factors.

Authors:  Peter W F Wilson; Henry R Black; Anthony N Fabricatore; Ira J Goldberg
Journal:  J Cardiometab Syndr       Date:  2008

3.  Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.

Authors:  A Dornhorst; H-J Lüddeke; S Sreenan; C Koenen; J B Hansen; A Tsur; L Landstedt-Hallin
Journal:  Int J Clin Pract       Date:  2007-03       Impact factor: 2.503

4.  Glucose homeostasis predicts weight gain: prospective and clinical evidence.

Authors:  Normand G Boulé; Jean-Philippe Chaput; Eric Doucet; Denis Richard; Jean-Pierre Després; Claude Bouchard; Angelo Tremblay
Journal:  Diabetes Metab Res Rev       Date:  2008-02       Impact factor: 4.876

5.  Short-term intensive insulin therapy in newly diagnosed type 2 diabetes.

Authors:  Edmond A Ryan; Sharleen Imes; Clarissa Wallace
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

Review 6.  Insulin resistance and blood pressure.

Authors:  Sonya Addison; Sameer Stas; Melvin R Hayden; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2008-08       Impact factor: 5.369

7.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  Cardiometabolic risk management in type 2 diabetes and obesity.

Authors:  Angela M Taylor
Journal:  Curr Diab Rep       Date:  2008-10       Impact factor: 4.810

9.  Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.

Authors:  Carol E Koro; Steven J Bowlin; Nancy Bourgeois; Donald O Fedder
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

10.  Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert Sherwin; Bernard Zinman
Journal:  Diabetes Care       Date:  2008-10-22       Impact factor: 17.152

View more
  7 in total

1.  Chronic insulin therapy reduces adipose tissue macrophage content in LDL-receptor-deficient mice.

Authors:  J Yoon; S Subramanian; Y Ding; S Wang; L Goodspeed; B Sullivan; J Kim; K D O'Brien; A Chait
Journal:  Diabetologia       Date:  2011-02-17       Impact factor: 10.122

2.  Clinical utility of insulin and insulin analogs.

Authors:  Ahter D Sanlioglu; Hasan Ali Altunbas; Mustafa Kemal Balci; Thomas S Griffith; Salih Sanlioglu
Journal:  Islets       Date:  2013-03-01       Impact factor: 2.694

3.  Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.

Authors:  J Rosenstock; A Jelaska; C Zeller; G Kim; U C Broedl; H J Woerle
Journal:  Diabetes Obes Metab       Date:  2015-07-14       Impact factor: 6.577

Review 4.  The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.

Authors:  Anne Pernille Ofstad; Dan Atar; Lars Gullestad; Gisle Langslet; Odd Erik Johansen
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 5.  A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes.

Authors:  Thomas Forst; Pratik Choudhary; Doron Schneider; Bruno Linetzky; Paolo Pozzilli
Journal:  Diabetes Metab Res Rev       Date:  2020-12-01       Impact factor: 4.876

6.  Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.

Authors:  Philip D Home; Roopa Mehta; Khadija A S Hafidh; Olesya Y Gurova; Agustina Alvarez; Paul Serafini; Mir-Masoud Pourrahmat
Journal:  Diabetes Obes Metab       Date:  2021-08-31       Impact factor: 6.408

7.  Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA.

Authors:  Lawrence Blonde; Luigi Meneghini; Xuejun Victor Peng; Anders Boss; Kyu Rhee; Alka Shaunik; Supriya Kumar; Sidhartha Balodi; Claire Brulle-Wohlhueter; Rory J McCrimmon
Journal:  Diabetes Ther       Date:  2018-03-29       Impact factor: 2.945

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.